Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Chemocentryx Inc
(NQ:
CCXI
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Oct 19, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Chemocentryx Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Two Down With Sanofi Bowing Out From Horizon Buyout Talks, Amgen Agrees To Buy For $116.5/Share
December 12, 2022
Via
Benzinga
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
November 23, 2022
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.
Via
Benzinga
ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual Meetings
October 17, 2022
From
ChemoCentryx, Inc.
Via
GlobeNewswire
Biotech Stocks Well-Positioned For The Fourth Quarter
October 12, 2022
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.
Via
Talk Markets
ChemoCentryx: Q2 Earnings Insights
August 09, 2022
ChemoCentryx (NASDAQ:CCXI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Via
Benzinga
3 Analysts Have This to Say About ChemoCentryx
August 05, 2022
ChemoCentryx (NASDAQ:CCXI) has observed the following analyst ratings within the last quarter:
Via
Benzinga
ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 05, 2022
From
ChemoCentryx, Inc.
Via
GlobeNewswire
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
September 20, 2022
We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022.
Via
Talk Markets
Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year
September 19, 2022
The biotech run off a June bottom is great — until you realize you could've netted more.
Via
Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
September 13, 2022
From
Scott+Scott Attorneys at Law LLP
Via
Business Wire
7 Dow Stocks With Superior Fundamentals
September 06, 2022
Robust Dow stocks offer attractive deals for patient investors amidst an unstable economic environment
Via
InvestorPlace
Healthcare Sector Still Looks Good But Lacks Momentum
September 06, 2022
The summer rally is over it’s a holiday weekend with low trading volume and bad news is pervasive. A decent jobs report on Friday brought in buyers in early hours until Russia intervened with a Nord...
Via
Talk Markets
ChemoCentryx's Return On Capital Employed Insights
September 01, 2022
According to data from Benzinga Pro, during Q2, ChemoCentryx's (NASDAQ:CCXI) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million.
Via
Benzinga
INVESTIGATION ALERT: Scott+Scott Attorneys at Law LLP Investigates ChemoCentryx, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CCXI
August 30, 2022
From
Scott+Scott Attorneys at Law LLP
Via
Business Wire
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
August 29, 2022
These names are benefitting from M&A, clinical data and promising regulatory actions.
Via
Investor's Business Daily
Whither Small Caps After Fed’s Tough Talk?
August 29, 2022
For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and...
Via
Talk Markets
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
August 23, 2022
The biopharma buying spree continued Tuesday with glaucoma drugs maker Aerie.
Via
Investor's Business Daily
Check your Portfolio for Small Cap Weighting: Growth, Innovation or Speculation?
August 15, 2022
The SPDR S&P Biotech ETF remains our key indicator for small cap biotechs. It is up 14.55% over one month at $93.78 but is still down 16% YTD. The Russell 2000 is up 16.5% over one month mirroring...
Via
Talk Markets
Why Jim Cramer Says This Financial Stock Is 'Terrific'
August 12, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Charles Schwab Corporation (NYSE: SCHW) is "terrific."
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
August 10, 2022
Via
Benzinga
Earnings Preview: ChemoCentryx
August 08, 2022
ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that ChemoCentryx...
Via
Benzinga
Small Cap Biotechs Perk Up On Dealmaking
August 06, 2022
With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology.
Via
Talk Markets
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
August 05, 2022
The Nasdaq and small caps rose while the S&P 500 is hitting resistance.
Via
Investor's Business Daily
Where ChemoCentryx Stands With Analysts
August 05, 2022
Over the past 3 months, 4 analysts have published their opinion on ChemoCentryx (NASDAQ:CCXI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
August 05, 2022
Upgrades
Via
Benzinga
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
August 05, 2022
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
Why NanoViricides Jumped Over 48%; Here Are 106 Biggest Movers From Yesterday
August 05, 2022
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) surged 109.2% to settle at $50.43 on Thursday after the company, and Amgen, announced an agreement under which Amgen will acquire the company for $52 per share...
Via
Benzinga
Amgen Narrows Sales Outlook Following Plans To Acquire ChemoCentryx
August 04, 2022
The company also reported a second-quarter beat and reiterated its earnings outlook.
Via
Investor's Business Daily
Gold Tops 1,800; Alibaba Reports Upbeat Results
August 04, 2022
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 75 points on Thursday
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.